Impact of community pharmaceutical care on patient health and quality of drug treatment in Parkinson's disease
Schroeder, Sabrina ; Martus, Peter ; Odin, Per LU
and Schaefer, Marion
(2012)
In International Journal of Clinical Pharmacy
34(5).
p.746-756
- Abstract
- Background The well-being of patients with Parkinson's disease may be improved by pharmaceutical care in community pharmacies. Objective To investigate the effects of standardised pharmaceutical care on health outcomes and quality of drug treatment in patients with Parkinson's disease. Setting Community pharmacies in Germany. Method An open-label, multicentre, longitudinal, parallel-group study was conducted in outpatients with idiopathic Parkinson's disease who were receiving anti-parkinsonian medication. Patients were recruited by 32 community pharmacists (pharmacy group) and local offices of the German Parkinson's disease patients' association (comparison group). All patients were assessed at baseline and at 8 months' follow-up. In the... (More)
- Background The well-being of patients with Parkinson's disease may be improved by pharmaceutical care in community pharmacies. Objective To investigate the effects of standardised pharmaceutical care on health outcomes and quality of drug treatment in patients with Parkinson's disease. Setting Community pharmacies in Germany. Method An open-label, multicentre, longitudinal, parallel-group study was conducted in outpatients with idiopathic Parkinson's disease who were receiving anti-parkinsonian medication. Patients were recruited by 32 community pharmacists (pharmacy group) and local offices of the German Parkinson's disease patients' association (comparison group). All patients were assessed at baseline and at 8 months' follow-up. In the intervening period, the pharmacists provided patients in the pharmacy group with standardised pharmaceutical care. Main outcome measure Mean change in symptom-related impairment of health status, assessed using the 23-item Parkinson's Scale Total Score. Results In total 235 patients were enrolled into the study (113 pharmacy group; 122 comparison group). Between-group analysis showed that the mean changes in the primary and secondary endpoints, all 23-item Parkinson's Scale sub-scores and the EuroQol 5-Dimension Questionnaire Index Score were significantly in favour of the pharmacy group after 8 months (p < 0.05 to p < 0.001), using a mixed model analysis. No significant changes were observed in prescribers' guideline adherence, but there was a significant decrease in the proportion of patients receiving inappropriate drugs according to the Beers List in the pharmacy group (p < 0.01). Conclusion This study shows that significant benefits in patient health outcomes and age-related quality of drug treatment were gained when patients with Parkinson's disease were provided with standardised pharmaceutical care in community pharmacies. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3174997
- author
- Schroeder, Sabrina
; Martus, Peter
; Odin, Per
LU
and Schaefer, Marion
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Community pharmacist, Germany, Health outcomes, Parkinson's disease, Pharmaceutical care, Quality of drug treatment
- in
- International Journal of Clinical Pharmacy
- volume
- 34
- issue
- 5
- pages
- 746 - 756
- publisher
- Springer
- external identifiers
-
- wos:000309676500013
- scopus:84867400679
- ISSN
- 2210-7703
- DOI
- 10.1007/s11096-012-9672-9
- language
- English
- LU publication?
- yes
- id
- 1312aece-932f-4d95-aa1d-62175c8f1d63 (old id 3174997)
- date added to LUP
- 2016-04-01 10:49:38
- date last changed
- 2022-12-10 02:59:36
@article{1312aece-932f-4d95-aa1d-62175c8f1d63,
abstract = {{Background The well-being of patients with Parkinson's disease may be improved by pharmaceutical care in community pharmacies. Objective To investigate the effects of standardised pharmaceutical care on health outcomes and quality of drug treatment in patients with Parkinson's disease. Setting Community pharmacies in Germany. Method An open-label, multicentre, longitudinal, parallel-group study was conducted in outpatients with idiopathic Parkinson's disease who were receiving anti-parkinsonian medication. Patients were recruited by 32 community pharmacists (pharmacy group) and local offices of the German Parkinson's disease patients' association (comparison group). All patients were assessed at baseline and at 8 months' follow-up. In the intervening period, the pharmacists provided patients in the pharmacy group with standardised pharmaceutical care. Main outcome measure Mean change in symptom-related impairment of health status, assessed using the 23-item Parkinson's Scale Total Score. Results In total 235 patients were enrolled into the study (113 pharmacy group; 122 comparison group). Between-group analysis showed that the mean changes in the primary and secondary endpoints, all 23-item Parkinson's Scale sub-scores and the EuroQol 5-Dimension Questionnaire Index Score were significantly in favour of the pharmacy group after 8 months (p < 0.05 to p < 0.001), using a mixed model analysis. No significant changes were observed in prescribers' guideline adherence, but there was a significant decrease in the proportion of patients receiving inappropriate drugs according to the Beers List in the pharmacy group (p < 0.01). Conclusion This study shows that significant benefits in patient health outcomes and age-related quality of drug treatment were gained when patients with Parkinson's disease were provided with standardised pharmaceutical care in community pharmacies.}},
author = {{Schroeder, Sabrina and Martus, Peter and Odin, Per and Schaefer, Marion}},
issn = {{2210-7703}},
keywords = {{Community pharmacist; Germany; Health outcomes; Parkinson's disease; Pharmaceutical care; Quality of drug treatment}},
language = {{eng}},
number = {{5}},
pages = {{746--756}},
publisher = {{Springer}},
series = {{International Journal of Clinical Pharmacy}},
title = {{Impact of community pharmaceutical care on patient health and quality of drug treatment in Parkinson's disease}},
url = {{http://dx.doi.org/10.1007/s11096-012-9672-9}},
doi = {{10.1007/s11096-012-9672-9}},
volume = {{34}},
year = {{2012}},
}